TMO Jan 2024 370.000 call
| Previous Close | 261.62 |
| Open | 261.62 |
| Bid | 222.70 |
| Ask | 231.00 |
| Strike | 370.00 |
| Expire Date | 2024-01-19 |
| Day's Range | 261.62 - 261.62 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ZacksHere's Why Investors Should Retain Thermo Fisher (TMO) Stock
Investors continue to be optimistic about Thermo Fisher's (TMO) continued strength across its end markets and the the execution of the growth strategy.
- Zacks
Thermo Fisher's (TMO) Unveils Orbitrap Astral Spectrometer
Thermo Fisher's (TMO) OrbitrapTM AstralTM mass spectrometer enables accurate and exact quantification in proteomics laboratories.
Motley Fool3 Healthcare Stocks That Would Have Doubled Your Investment in 5 Years
A big allure of investing in healthcare is that the industry tends to have stocks stable enough to provide you with some long-term safety. Given that the need for healthcare will only grow with an aging population, the industry is also home to some solid growth stocks. Three relatively safe healthcare stocks that have doubled in value over the past five years include Thermo Fisher Scientific (NYSE: TMO), McKesson (NYSE: MCK), and Intuitive Surgical (NASDAQ: ISRG).
Simply Wall St.Thermo Fisher Scientific Inc.'s (NYSE:TMO) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
It is hard to get excited after looking at Thermo Fisher Scientific's (NYSE:TMO) recent performance, when its stock has...
Business WireThermo Fisher Scientific Introduces Groundbreaking Mass Spectrometer to Revolutionize Biological Discovery
WALTHAM, Mass., June 05, 2023--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, one of the most significant advancements in mass spectrometry in 15 years. The new Astral analyzer combines fast throughput, high sensitivity and deep proteome coverage to allow researchers worldwide to uncover proteins that previously evaded detection and make breakthrough discoveries more efficiently than ever.
ZacksThermo Fisher Scientific (TMO) Gains But Lags Market: What You Should Know
Thermo Fisher Scientific (TMO) closed at $520.14 in the latest trading session, marking a +0.15% move from the prior day.
- Simply Wall St.
Does This Valuation Of Thermo Fisher Scientific Inc. (NYSE:TMO) Imply Investors Are Overpaying?
Key Insights Thermo Fisher Scientific's estimated fair value is US$388 based on 2 Stage Free Cash Flow to Equity Thermo...
ZacksThermo Fisher (TMO) Down 4.1% Since Last Earnings Report: Can It Rebound?
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Thermo Fisher Scientific (NYSE:TMO) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Business WireThermo Fisher Scientific Declares Quarterly Dividend
WALTHAM, Mass., May 24, 2023--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.35 per common share, payable on July 14, 2023, to shareholders of record as of June 15, 2023.
ZacksThermo Fisher (TMO) Expands Manufacturing Facility in APAC
Thermo Fisher (TMO) latest expansion will enable it to better assist clients in accelerating their research, development and marketing of medications and vaccines in the Asia-Pacific region.
Business WireThermo Fisher Scientific Hosts 2023 Investor Day
WALTHAM, Mass., May 24, 2023--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its 2023 Investor Day today and provided an in-depth review of the Company’s proven growth strategy and its industry-leading businesses: Life Science Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.
ZacksThermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays
Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.
Business WireThermo Fisher Scientific to Present at Bernstein 39th Annual Strategic Decisions Conference on May 31st, 2023
WALTHAM, Mass., May 22, 2023--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Bernstein 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023 at 11:00 a.m. (EDT).
ZacksBuy These Standout Large-Cap Stocks for Long-Term Upside?
There are many great stocks with proven and resilient businesses that investors should feel comfortable buying now at rather attractive levels and holding for the long haul. The two stocks we dive into today are Thermo Fisher Scientific Inc. (TMO) and Visa Inc. (V).
- Reuters
UPDATE 1-Thermo Fisher's test to detect pregnancy-related complication gets FDA nod
The U.S. Food and Drug Administration (FDA) has cleared Thermo Fisher Scientific Inc's test, the first of its kind in the country, to detect women with risk of severe preeclampsia, the company said on Friday. Preeclampsia is a leading cause of mortality in pregnant women globally, where they could experience high blood pressure after 20 weeks of pregnancy and during the postpartum period. The condition happens in about 1 in 25 pregnancies in the United States, according to the U.S. Centers for Disease Control and Prevention.
Business WireThermo Fisher Scientific Announces FDA Clearance of Breakthrough Immunoassays to Aid in the Risk Assessment of Preeclampsia
WALTHAM, Mass., May 19, 2023--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Thermo Scientific B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR novel biomarkers, the first and only immunoassays to receive breakthrough designation and clearance for the risk assessment and clinical management of preeclampsia, a severe pregnancy complication.
- Simply Wall St.
Thermo Fisher Scientific's (NYSE:TMO) investors will be pleased with their impressive 144% return over the last five years
Thermo Fisher Scientific Inc. ( NYSE:TMO ) shareholders might be concerned after seeing the share price drop 11% in the...
- Zacks
The Zacks Analyst Blog Highlights Broadcom, Bank of America, Thermo Fisher Scientific, Chubb Limited and Aon
Broadcom, Bank of America, Thermo Fisher Scientific, Chubb Limited and Aon are part of the Zacks top Analyst Blog.
ZacksTop Stock Reports for Broadcom, Bank of America & Thermo Fisher Scientific
Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Bank of America (BAC) and Thermo Fisher Scientific (TMO).
Business WireThermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report
WALTHAM, Mass., May 17, 2023--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today released its annual Corporate Social Responsibility (CSR) report. The report highlights the company’s commitment to society and stakeholders and provides insight into its CSR progress and environmental, social and governance (ESG) efforts.
- Zacks
Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing
Thermo Fisher's (TMO) latest collaboration with Pfizer is set to enhance localized access to NGS-based testing capabilities for breast and lung cancer across international markets.
Business WireThermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next-Generation Sequencing-Based Testing for Cancer Patients in International Markets
WALTHAM, Mass., May 09, 2023--Pfizer and Thermo Fisher Scientific Inc. (NYSE: TMO) today announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable. Access to local NGS testing can help to provide faster analysis of associated ge
- Simply Wall St.
Declining Stock and Solid Fundamentals: Is The Market Wrong About Thermo Fisher Scientific Inc. (NYSE:TMO)?
Thermo Fisher Scientific (NYSE:TMO) has had a rough three months with its share price down 7.2%. However, a closer look...
Motley FoolGot $5,000? Buy These 2 Stalwart Stocks and Hold Them Forever
Packing your portfolio with risky hyper-growth stocks might make you feel like a genius during a bull market, but when there's a downturn, your smile just might get turned upside down. As exciting as seeing rapidly rising share prices might be, your portfolio needs to be well-diversified, and that means you need a few companies that are stable in the face of turmoil, not to mention being capable of delivering some growth all the time. Thermo Fisher Scientific (NYSE: TMO) is a sturdy stock that's fit for holding for decades because it's one of the businesses that makes the entire biopharma sector run.
